Adverum Biotechnologies to Host a Conference Call and Webcast to Report First Quarter 2020 Financial Results and Provide Corporate Update

Rhea-AI Summary

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) will host a conference call on May 28, 2020, at 1:30 PM PT to discuss its Q1 2020 financial results and business updates. The call will be accessible via audio webcast on the company's website. Participants are encouraged to dial in 15 minutes early. Adverum is focused on addressing unmet medical needs in ocular and rare diseases, particularly with its gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration.

Positive

• Anticipation of Q1 2020 financial results and business updates from Adverum Biotechnologies.
• Focus on innovative gene therapy candidate ADVM-022 for wet age-related macular degeneration.

Negative

• None.

REDWOOD CITY, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and audio webcast on Thursday, May 28, 2020 at 1:30 pm PT / 4:30 pm ET to report its first quarter 2020 financial results and provide an update on recent business progress.

The live audio webcast will be accessible under Events and Presentations in the Investors section of the company's website. To participate in the conference call, dial 1-866-420-8347 (domestic) or 1-409-217-8241 (international) and refer to the “Adverum Biotechnologies’ First Quarter 2020 Earnings Call.” It is recommended call participants dial in 15 minutes in advance. The archived audio webcast will be available on the Adverum website following the call and will be available for 30 days.

About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.

Investor and Media Inquiries:

Investors:
Myesha Lacy
Adverum Biotechnologies, Inc.

1-650-649-1257

Media:
Cherilyn Cecchini, M.D.
LifeSci Communications

1-646-876-5196

FAQ

When will Adverum Biotechnologies report its Q1 2020 financial results?

Adverum Biotechnologies will report its Q1 2020 financial results on May 28, 2020.

What is ADVM-022 and its significance?

ADVM-022 is a gene therapy candidate developed by Adverum for treating wet age-related macular degeneration.

How can I participate in the Adverum Q1 earnings call?

To participate in the earnings call, dial 1-866-420-8347 (domestic) or 1-409-217-8241 (international) and refer to the "Adverum Biotechnologies’ First Quarter 2020 Earnings Call."

Where can I access the Adverum earnings call webcast?

The earnings call will be available via audio webcast on Adverum's website, along with an archived version for 30 days after the call.